Latigo director granted 105K stock options at $18
Latigo Biotherapeutics, Inc. (LTGO) reported that director Todd N. Smith received a grant of stock options for 105,542 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Latigo Biotherapeutics, Inc. (LTGO) reported that director Todd N. Smith received a grant of stock options for 105,542 shares of common stock. The options have an exercise price of $18.00 per share, expire on August 5, 2036, and were acquired as a director stock option award. All 105,542 options are held directly and will vest in 36 equal monthly installments after May 30, 2026.
Insider Trade Summary
Grant/Award: 105,542 shares
Grant/Award
1 txn
Insider
SMITH TODD N
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Director Stock Option (right to buy) F1 | 105,542 | $0.00 | $0.00 |
Holdings After Transaction:
Director Stock Option (right to buy) — 105,542 contracts (Direct)
Footnotes (1)
- F1. The shares subject to this option shall vest in 36 equal monthly installments after May 30, 2026.
Key Figures
Options Granted: 105,542 shares
Exercise Price: $18.00 per share
Underlying Shares: 105,542 shares
+3 more
6 metrics
Options Granted
105,542 shares
Director stock option grant reported by Todd N. Smith
Exercise Price
$18.00 per share
Conversion or exercise price of the director stock options
Underlying Shares
105,542 shares
Common stock underlying the director stock options
Expiration Date
August 5, 2036
Expiration of the director stock options
Vesting Schedule
36 equal monthly installments
Options vest in 36 monthly installments after May 30, 2026
Holdings After Transaction
105,542 options
Total derivative securities held directly after the grant
Key Terms
Director Stock Option, exercise price, vesting, expiration date
4 terms
Director Stock Option financial
"security_title: Director Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 18.0000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"shares subject to this option shall vest in 36 equal monthly"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: 2036-08-05"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What transaction did LTGO director Todd N. Smith report on this Form 4?
Todd N. Smith reported a grant of 105,542 director stock options in Latigo Biotherapeutics, Inc. These options relate to common stock and represent a compensation-related acquisition rather than an open-market trade.
What is the exercise price of the stock options granted to the LTGO director?
The stock options granted to the LTGO director have an exercise price of $18.00 per share. This is the price at which the director can purchase Latigo Biotherapeutics common stock upon exercising the options.
When do the newly granted LTGO options to Todd N. Smith expire?
The options granted to Todd N. Smith in LTGO expire on August 5, 2036. After this expiration date, any unexercised options will lapse and can no longer be converted into shares of common stock.
How and when will Todd N. Smith’s LTGO stock options vest?
The LTGO options will vest in 36 equal monthly installments after May 30, 2026. This means the director gains exercisable rights to a portion of the options each month over a three-year period following that date.
How many LTGO options does Todd N. Smith hold after this reported grant?
Following the reported grant, Todd N. Smith holds 105,542 stock options in LTGO directly. All of these options relate to Latigo Biotherapeutics common stock and are subject to the stated vesting schedule and expiration date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates